Can losartan enhance the effects of cognitive behavioural therapy in the treatment of panic disorder?

Not Applicable

Completed

• Conditions: Panic disorder; Mental and Behavioural Disorders; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: ISRCTN94854860
• Lead Sponsor: niversity of Oxford

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-02-03
• Study Completion: 2023-03-31
• Last Update Posted: 10 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Participant is willing and able to give informed consent for participation in the study and to comply with all study requirements
2. Aged 18 years or above
3. Diagnosed with DSM­IV panic disorder
4. At least moderate avoidance of agoraphobic situations

*Participants with MRI contraindications (e.g. pacemaker, metal implant, left-­handedness) can be included in the study but will not undergo the MRI scan study component.

Exclusion Criteria

1. Female participant who is pregnant or breast­feeding
2. CNS­-active medication during the last 6 weeks
3. Current blood pressure or other heart medication (especially aliskiren or beta blockers)
4. Intravascular fluid depletion
5. Impaired liver or kidney function
6. Lifetime history of epilepsy or other neurological disease, systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant’s ability to participate in the study
7. Lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder
8. Insufficient English skills
9. Participated in another study involving certain medication during the last 6 weeks
10. Patient unable to refrain from benzodiazepines 48 hours before treatment and testing sessions

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Symptom severity is measured using the clinician-rated questionnaires Panic Disorder Severity Scale and Clinical Global Impression Scale at baseline, one month and six months post-treatment, as well as the self-report questionnaires State-Trait Anxiety Inventory, Beck Depression Inventory, Panic Attack Scale, Agoraphobic Cognitions Questionnaire, Body Sensations Questionnaire, Mobility Inventory, Visual Analogue Scales during Stress at baseline, one day, one month and six months post-treatment.

Secondary Outcome Measures

Name	Time	Method
Emotion processing is measured using behavioural reaction time tasks at baseline and one day post treatment, as well as using a functional MRI one day post treatment.